Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberta Caputo

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 1, 2023
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trialLuca Malorni, Giampaolo Bianchini, Roberta Caputo, et al.
Eclinicalmedicine|October 13, 2025
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: a systematic review and network meta-analysisRoberto Buonaiuto, Mario Fordellone, Aldo Caltavituro, et al.
Cancer Treatment Reviews|May 22, 2026
Central nervous system and leptomeningeal metastases in patients with HER2-positive breast cancer: A comprehensive review and therapeutic algorithm proposalAldo Caltavituro, Roberto Buonaiuto, Alessandra Longobardi, et al.
The Oncologist|January 26, 2026
Clinical characteristics and Drug-Drug interactions in HER2+ breast cancer treated with T-DXd: Real-World data from the DE-REAL studySimona Pisegna, Simone Scagnoli, Gabriella Gentile, et al.
ESMO Open|August 2, 2017
Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)Michele Orditura, Adriano Gravina, Ferdinando Riccardi, et al.
NPJ Precision Oncology|January 22, 2025
Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab DeruxtecanAlessandra Fabi, Alessandro Rossi, Roberta Caputo, et al.
Eclinicalmedicine|April 30, 2024
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trialsEva Blondeaux, Wanling Xie, Luca Carmisciano, et al.
The Oncologist|November 23, 2023
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL StudyAndrea Botticelli, Roberta Caputo, Simone Scagnoli, et al.
Breast (Edinburgh, Scotland)|August 10, 2018
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancerAlessandra Fabi, Daniele Alesini, Enrichetta Valle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
Role of ctDNA in predicting the outcome of patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole: BioItaLEE trialGiampaolo Bianchini, Luca Malorni, Roberta Caputo, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
European Journal of Cancer (Oxford, England : 1990)|April 1, 2023
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trialLuca Malorni, Giampaolo Bianchini, Roberta Caputo, et al.
Eclinicalmedicine|October 13, 2025
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: a systematic review and network meta-analysisRoberto Buonaiuto, Mario Fordellone, Aldo Caltavituro, et al.
Cancer Treatment Reviews|May 22, 2026
Central nervous system and leptomeningeal metastases in patients with HER2-positive breast cancer: A comprehensive review and therapeutic algorithm proposalAldo Caltavituro, Roberto Buonaiuto, Alessandra Longobardi, et al.
The Oncologist|January 26, 2026
Clinical characteristics and Drug-Drug interactions in HER2+ breast cancer treated with T-DXd: Real-World data from the DE-REAL studySimona Pisegna, Simone Scagnoli, Gabriella Gentile, et al.
ESMO Open|August 2, 2017
Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)Michele Orditura, Adriano Gravina, Ferdinando Riccardi, et al.
NPJ Precision Oncology|January 22, 2025
Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab DeruxtecanAlessandra Fabi, Alessandro Rossi, Roberta Caputo, et al.
Eclinicalmedicine|April 30, 2024
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trialsEva Blondeaux, Wanling Xie, Luca Carmisciano, et al.
The Oncologist|November 23, 2023
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL StudyAndrea Botticelli, Roberta Caputo, Simone Scagnoli, et al.
Breast (Edinburgh, Scotland)|August 10, 2018
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancerAlessandra Fabi, Daniele Alesini, Enrichetta Valle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
Role of ctDNA in predicting the outcome of patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole: BioItaLEE trialGiampaolo Bianchini, Luca Malorni, Roberta Caputo, et al.
Pageof 5